# Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia

> **NCT05993949** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Stanford University** · enrollment: 8 (actual)

## Conditions studied

- Lymphoblastic Leukemia

## Interventions

- **DRUG:** Dasatinib

## Key facts

- **NCT ID:** NCT05993949
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-10-02
- **Primary completion:** 2027-06
- **Final completion:** 2027-06
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2025-09-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05993949

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05993949, "Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05993949. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*